Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cytodyn Inc
(OP:
CYDY
)
0.1150
UNCHANGED
Streaming Delayed Price
Updated: 3:59 PM EST, Nov 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Cytodyn Inc
< Previous
1
2
3
4
Next >
CytoDyn Comments on Rosenbaum/Patterson Activist Group “Plan”
September 29, 2021
From
CytoDyn Inc.
Via
Business Wire
Group of CytoDyn Stockholders Releases White Paper Regarding Company’s Extremely Unfavorable Borrowing Practices
September 27, 2021
From
Gasthalter & Co. on behalf of CytoDyn Inc. shareholders
Via
Business Wire
CytoDyn to Present at Emerging Growth Conference on September 29 Followed by Live Q/A
September 27, 2021
From
CytoDyn Inc.
Via
Business Wire
Group of CytoDyn Stockholders Shares Strategic Plan to Obtain Cancer Therapy Approval for Leronlimab
September 24, 2021
From
Gasthalter & Co. on behalf of CytoDyn Inc. shareholders
Via
Business Wire
Accelerated Development of COVID-19 Vaccines to Combat Potential for Possible Future Viral Pathogens and Variants
September 22, 2021
Via
FinancialNewsMedia
Exposures
COVID-19
CytoDyn Receives Clearance from Brazil’s FDA (ANVISA) to Commence a Pivotal Phase 3 Trial in Critically Ill COVID-19 Patients with IV Administration of Four Doses (700mg/week)
September 22, 2021
From
CytoDyn Inc.
Via
Business Wire
CytoDyn’s Chairman, CMO, and Head of Business Development Dr. Scott A. Kelly to Present at the World Antiviral Congress 2021
September 21, 2021
From
CytoDyn Inc.
Via
Business Wire
Group of CytoDyn Stockholders Announces Federal Court Dismisses Litigation Brought by Company
September 20, 2021
From
Gasthalter & Co. on behalf of CytoDyn Inc. shareholders
Via
Business Wire
CytoDyn Announces Resolution of Federal Litigation with Rosenbaum/Patterson Activist Group
September 20, 2021
From
CytoDyn Inc.
Via
Business Wire
Bruce Patterson, M.D., Director Candidate for CytoDyn Board, Presents at International COVID Summit
September 17, 2021
From
Gasthalter & Co. on behalf of CytoDyn Inc. shareholders
Via
Business Wire
Glancy Prongay & Murray LLP Announces Investigation of CytoDyn Inc.
September 15, 2021
From
Glancy Prongay & Murray LLP
Via
Business Wire
Why Experts Believe Antibody Treatments Hold The Potential To Reduce Need For Hospitalization For COVID-19 Patients
September 14, 2021
Via
FinancialNewsMedia
Exposures
COVID-19
Group of CytoDyn Stockolders Responds to Misleading Company News Release
September 07, 2021
From
Gasthalter & Co. on behalf of CytoDyn Inc. shareholders
Via
Business Wire
The Daily Biotech Pulse: Apellis Sinks On Data, Endo Shines On Opioid Litigation Settlement, T2 Biosystems Soars On Mutant Detection Ability of COVID Test
September 10, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 9) Adagio Therapeutics, Inc. (...
Via
Benzinga
CytoDyn Highlights Court Ordering Rosenbaum/Patterson Group to Comply With the Federal Securities Laws
September 02, 2021
From
CytoDyn Inc.
Via
Business Wire
Group of CytoDyn Stockholders Warns Stockholders of Board’s Continued Value Destruction and Failures
September 02, 2021
From
Gasthalter & Co. on behalf of CytoDyn Inc. shareholders
Via
Business Wire
Group of CytoDyn Stockholders Files Lawsuit to Force Company to Allow Stockholders to Vote for Alternative Director Nominees
August 26, 2021
From
Gasthalter & Co. on behalf of CytoDyn Inc. shareholders
Via
Business Wire
CytoDyn Urges Shareholders to Ignore Proxy Cards from Rosenbaum/Patterson Group
August 25, 2021
From
CytoDyn
Via
Business Wire
Group of CytoDyn Stockholders Responds to Highly Misleading Company Release
August 19, 2021
From
Gasthalter & Co. on behalf of CytoDyn Inc. shareholders
Via
Business Wire
CytoDyn Provides Update on Rosenbaum/Patterson Group Litigation
August 19, 2021
From
CytoDyn Inc.
Via
Business Wire
CytoDyn Files Lawsuit Against Rosenbaum/Patterson Activist Group for Misleading Shareholders and Waging an Unlawful Proxy Contest
August 05, 2021
From
CytoDyn Inc.
Via
Business Wire
CytoDyn Receives Clearance from Brazil’s ANVISA to Commence Phase 3 Trial for Severe COVID-19 Patients
August 03, 2021
From
CytoDyn Inc.
Via
Business Wire
CytoDyn Announces That Director Nominations by Rosenbaum/Patterson Activist Group Are Invalid
August 02, 2021
From
CytoDyn Inc.
Via
Business Wire
CytoDyn Inc. (OTC: CYDY) Long Term Investor Notice: Investigation of Potential Wrongdoing
July 28, 2021
San Diego, CA -- (SBWIRE) -- 07/28/2021 -- An investigation on behalf of current long term investors in CytoDyn Inc. (OTC: CYDY) shares over possible breaches of fiduciary duty by certain officers and...
Via
SBWire
Topics
Lawsuit
Exposures
COVID-19
Financial
Legal
OTC Markets Hits Major Milestones in Mid-Year Along With Big Volume and Gaining Securities
July 28, 2021
Photo by Kyrie Kim on Unsplash In a similar vein to 2020, the market’s volatility to start 2021 gave way to less volatility in the second quarter, and even less volatility...
Via
Benzinga
Group of Cytodyn Stockholders Nominates Five Highly Qualified Director Candidates to Replace Board Responsible for Mismanagement and Value Destruction
July 01, 2021
From
Gasthalter & Co. on behalf of CytoDyn Inc. shareholders
Via
Business Wire
What's Behind This Wild-Card Coronavirus Stock?
June 08, 2021
Failure is not an option for this small-cap biotech developing a COVID-19 treatment.
Via
The Motley Fool
Exposures
COVID-19
CytoDyn Plans To Send Topline Data From COVID-19 Trial Of Leronlimab To Regulators In India, Philippines
May 18, 2021
After facing rebuke from FDA, CytoDyn Inc (OTC: CYDY) plans to submit the topline results of its CD12 Phase 3 trial of Vyrologix (leronlimab-PRO 140...
Via
Benzinga
Exposures
COVID-19
Product Safety
CytoDyn Stock Falls After FDA Rebukes Claims On COVID-19 Treatment
May 18, 2021
The FDA has accused CytoDyn Inc (OTC: CYDY) of trying to pick and choose data from two failed studies of leronlimab in COVID-19 patients to claim the drug is...
Via
Benzinga
Exposures
COVID-19
Product Safety
The Daily Biotech Pulse: Spero Secures NIAID Funding, GlaxoSmithKline Releases COVID-19 Data, BioNTech Gets New CFO
May 18, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 17) Alexion Pharmaceuticals, Inc...
Via
Benzinga
Exposures
COVID-19
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.